Kidiaven Nouveau-Ne 1

Valine, Acetylcysteine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine and Phenylalanine, the active ingredients in Kidiaven Nouveau‑Ne 1, are an amino acid supplement presented as a parenteral solution for injection use. It provides essential and non‑essential amino acids to support protein synthesis and nutritional needs in infants and children who cannot meet requirements orally.

GNH USA supplies Kidiaven Nouveau‑Ne 1 as a licensed, GDP‑compliant international pharmaceutical supplier serving major hospitals, transplant centres, regional oncology centres, pharmacies and clinics globally worldwide.

Kidiaven Nouveau‑Ne 1 is used in parenteral nutrition to provide amino acids for patients with inadequate oral intake. - Parenteral nutrition for infants and children: Supplies a balanced mix of essential and non‑essential amino acids to meet growth and metabolic demands. - Support of protein synthesis in patients unable to meet nutritional needs orally: Enhances nitrogen balance and promotes tissue repair. - Preterm neonates requiring amino acid supplementation: Provides critical substrates for rapid growth and organ development.

Kidiaven Nouveau‑Ne 1 may be associated with the following adverse reactions.

Common Side Effects: - Infusion site erythema or pain: mild local irritation at the catheter site. - Nausea or vomiting: transient gastrointestinal discomfort. - Transient metabolic alkalosis: mild shift in acid‑base balance. - Hyperglycemia: elevation of blood glucose levels, especially in diabetic patients. - Electrolyte disturbances (e.g., mild hypernatremia): changes in serum electrolytes.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of hypotension, bronchospasm, or urticaria. - Hyperosmolarity leading to renal dysfunction: impaired kidney function due to high solute load. - Metabolic acidosis: significant acid‑base imbalance requiring intervention. - Thrombophlebitis: inflammation and clot formation in the vein. - Sepsis related to catheter infection: systemic infection originating from the infusion line.

When using Kidiaven Nouveau‑Ne 1, clinicians should observe the following precautions. - Assess renal function: adjust infusion rate in patients with impaired kidney function. - Monitor electrolytes: regular checks of serum sodium, potassium, and calcium levels. - Evaluate acid‑base status: watch for metabolic alkalosis or acidosis during therapy. - Use aseptic technique: prevent catheter‑related infections. - Adjust for hepatic impairment: consider reduced metabolism of certain amino acids. - Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake.

Kidiaven Nouveau‑Ne 1 can interact with other agents administered concurrently.

Major Interactions (Avoid): - High‑dose glucocorticoids: may increase protein catabolism, reducing efficacy. - Loop diuretics: can exacerbate electrolyte imbalances, especially potassium loss.

Moderate Interactions (Monitor Closely): - Insulin therapy: amino acids may affect glucose control, requiring dose adjustment. - Other parenteral nutrition components: risk of incompatibility or precipitation. - Anticoagulants (heparin): may increase risk of bleeding at infusion site. - Mineral supplements (e.g., calcium, phosphate): monitor for precipitation in the solution.